Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial was:
- to assess whether Reparixin leads to improved transplant outcome as measured by glycaemic
control following intra-hepatic infusion of pancreatic islets in patients with Type 1
diabetes (T1D). The safety of Reparixin in the specific clinical setting was also evaluated.
Background: The chemokine CXCL8 plays a key role in the recruitment and activation of
polymorphonuclear neutrophils in post-ischemia reperfusion injury after organ
transplantation. Reparixin is the first low molecular weight blocker of CXCL8 biological
activity in clinical development. Thus, the use of reparixin may emerge as a potential key
component in the sequentially integrated approach to immunomodulation and control of non
specific inflammatory events surrounding the early phases of pancreatic islet transplantation
in T1D patients.